The Diagnosis and Management of Retroperitoneal Sarcoma

Sinziana Dumitra, Alessandro Gronchi

Research output: Contribution to journalArticle

Abstract

Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure. In order to achieve negative margins, multivisceral en bloc resection is often necessary. Neoadjuvant therapies (chemotherapy, external beam radiation, or combination radiation and chemotherapy) are safe in well-selected patients and may be considered after careful review by a multidisciplinary sarcoma tumor board when the recurrence risk is high.

Original languageEnglish
Pages (from-to)464-9
Number of pages6
JournalOncology
Volume32
Issue number9
Publication statusPublished - Sep 15 2018

Fingerprint

Sarcoma
Radiation
Neoadjuvant Therapy
Combination Drug Therapy
Neoplasms
Pathology
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Dissection/methods
  • Humans
  • Neoadjuvant Therapy/methods
  • Neoplasm Staging
  • Patient Care Team
  • Patient Selection
  • Prognosis
  • Retroperitoneal Neoplasms/pathology
  • Sarcoma/pathology

Cite this

The Diagnosis and Management of Retroperitoneal Sarcoma. / Dumitra, Sinziana; Gronchi, Alessandro.

In: Oncology, Vol. 32, No. 9, 15.09.2018, p. 464-9.

Research output: Contribution to journalArticle

Dumitra, Sinziana ; Gronchi, Alessandro. / The Diagnosis and Management of Retroperitoneal Sarcoma. In: Oncology. 2018 ; Vol. 32, No. 9. pp. 464-9.
@article{8598205265494036a7ef7c6b48d34d74,
title = "The Diagnosis and Management of Retroperitoneal Sarcoma",
abstract = "Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure. In order to achieve negative margins, multivisceral en bloc resection is often necessary. Neoadjuvant therapies (chemotherapy, external beam radiation, or combination radiation and chemotherapy) are safe in well-selected patients and may be considered after careful review by a multidisciplinary sarcoma tumor board when the recurrence risk is high.",
keywords = "Dissection/methods, Humans, Neoadjuvant Therapy/methods, Neoplasm Staging, Patient Care Team, Patient Selection, Prognosis, Retroperitoneal Neoplasms/pathology, Sarcoma/pathology",
author = "Sinziana Dumitra and Alessandro Gronchi",
year = "2018",
month = "9",
day = "15",
language = "English",
volume = "32",
pages = "464--9",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - The Diagnosis and Management of Retroperitoneal Sarcoma

AU - Dumitra, Sinziana

AU - Gronchi, Alessandro

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure. In order to achieve negative margins, multivisceral en bloc resection is often necessary. Neoadjuvant therapies (chemotherapy, external beam radiation, or combination radiation and chemotherapy) are safe in well-selected patients and may be considered after careful review by a multidisciplinary sarcoma tumor board when the recurrence risk is high.

AB - Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure. In order to achieve negative margins, multivisceral en bloc resection is often necessary. Neoadjuvant therapies (chemotherapy, external beam radiation, or combination radiation and chemotherapy) are safe in well-selected patients and may be considered after careful review by a multidisciplinary sarcoma tumor board when the recurrence risk is high.

KW - Dissection/methods

KW - Humans

KW - Neoadjuvant Therapy/methods

KW - Neoplasm Staging

KW - Patient Care Team

KW - Patient Selection

KW - Prognosis

KW - Retroperitoneal Neoplasms/pathology

KW - Sarcoma/pathology

M3 - Article

C2 - 30248168

VL - 32

SP - 464

EP - 469

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -